Ruxolitinib combined with azithromycin for scrub typhus-associated hemophagocytic lymphohistiocytosis in a child: a case report and narrative literature review - Summary - MDSpire
Advertisement
Ruxolitinib combined with azithromycin for scrub typhus-associated hemophagocytic lymphohistiocytosis in a child: a case report and narrative literature review
To report the first case of ruxolitinib treatment in pediatric scrub typhus-associated hemophagocytic lymphohistiocytosis (HLH), a rare but serious condition, and review existing literature on the condition.
Key Findings:
The patient met six of eight HLH-2004 diagnostic criteria.
Ruxolitinib was associated with rapid clinical improvement, although causality cannot be established due to concurrent therapies.
Among reviewed cases, 64.2% received corticosteroids and 50.7% received intravenous immunoglobulin.
Interpretation:
This case presents observations regarding ruxolitinib combined with azithromycin in scrub typhus-associated HLH.
Limitations:
Causal attribution of clinical improvement to ruxolitinib is uncertain due to concurrent therapies.
The literature review is limited by case-report bias and confounding factors.
Conclusion:
This is the first report of JAK1/2 inhibitor therapy in scrub typhus-associated HLH.
